A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment

Sitagliptin is the first dipeptidylpeptidase-4 inhibitor to be used in the management of type 2 diabetes. It is widely used as an add-on therapy to ongoing management or as monotherapy where it is deemed necessary. It has been found to be beneficial in improving β-cell function and glycemic control,...

Descripción completa

Detalles Bibliográficos
Autores principales: Eligar, Vinay S, Bain, Stephen C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3770622/
https://www.ncbi.nlm.nih.gov/pubmed/24039399
http://dx.doi.org/10.2147/DDDT.S32331
_version_ 1782284116472889344
author Eligar, Vinay S
Bain, Stephen C
author_facet Eligar, Vinay S
Bain, Stephen C
author_sort Eligar, Vinay S
collection PubMed
description Sitagliptin is the first dipeptidylpeptidase-4 inhibitor to be used in the management of type 2 diabetes. It is widely used as an add-on therapy to ongoing management or as monotherapy where it is deemed necessary. It has been found to be beneficial in improving β-cell function and glycemic control, and also is used in special circumstances like chronic kidney disease, with appropriate dose reductions. Overall, cardiovascular outcomes are no different from other oral hypoglycemic agents. In this review article we have summarized all the previous studies relevant to sitagliptin use in clinical practice and emphasized its use in various stages of chronic kidney disease.
format Online
Article
Text
id pubmed-3770622
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-37706222013-09-13 A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment Eligar, Vinay S Bain, Stephen C Drug Des Devel Ther Review Sitagliptin is the first dipeptidylpeptidase-4 inhibitor to be used in the management of type 2 diabetes. It is widely used as an add-on therapy to ongoing management or as monotherapy where it is deemed necessary. It has been found to be beneficial in improving β-cell function and glycemic control, and also is used in special circumstances like chronic kidney disease, with appropriate dose reductions. Overall, cardiovascular outcomes are no different from other oral hypoglycemic agents. In this review article we have summarized all the previous studies relevant to sitagliptin use in clinical practice and emphasized its use in various stages of chronic kidney disease. Dove Medical Press 2013-08-30 /pmc/articles/PMC3770622/ /pubmed/24039399 http://dx.doi.org/10.2147/DDDT.S32331 Text en © 2013 Eligar and Bain. This work is published by Dove Medical Press Ltd, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Ltd, provided the work is properly attributed.
spellingShingle Review
Eligar, Vinay S
Bain, Stephen C
A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment
title A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment
title_full A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment
title_fullStr A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment
title_full_unstemmed A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment
title_short A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment
title_sort review of sitagliptin with special emphasis on its use in moderate to severe renal impairment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3770622/
https://www.ncbi.nlm.nih.gov/pubmed/24039399
http://dx.doi.org/10.2147/DDDT.S32331
work_keys_str_mv AT eligarvinays areviewofsitagliptinwithspecialemphasisonitsuseinmoderatetosevererenalimpairment
AT bainstephenc areviewofsitagliptinwithspecialemphasisonitsuseinmoderatetosevererenalimpairment
AT eligarvinays reviewofsitagliptinwithspecialemphasisonitsuseinmoderatetosevererenalimpairment
AT bainstephenc reviewofsitagliptinwithspecialemphasisonitsuseinmoderatetosevererenalimpairment

Ejemplares similares